Thinking Allowed

medical / technology / education / art / flub

showing posts for 'agonist'

PAIRED: A New Multi-agent Approach for Adversarial Environment Generation

This Google AI blog describes a method for machine learning using paired agents. The gap between the one that did the best and the one that did the worst is regret. That feeling of 'could have done' better is what pushes the 'unsupervised environment design' algorithm towards a better solution. "The...
Source: googleblog.com

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost

Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis: Objective To compare the efficacy, safety, and cost effectiveness of direct acting oral anticoagulants (DOACs) for patients with atrial fibrillation. Design...
Source: bmj.com

Is Exenatide a Treatment for Parkinson’s Disease? Athauda, Dilan. Wyse, Richard. Brundin, Patrik. Foltynie, Thomas. Journal

Is Exenatide a Treatment for Parkinson’s Disease? Athauda, Dilan. Wyse, Richard. Brundin, Patrik. Foltynie, Thomas. Journal of Parkinson's Disease. "There is growing interest in the use of glucagon-like peptide-1 agonists as treatments for Parkinson’s disease following the recent publication...
Source: iospress.com

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents Vallöf,

The glucagon‐like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents Vallöf, Daniel. Maccioni, Paola. Colombo, Giancarlo. Mandrapa, Minja. Jörnulf, Julia Winsa. Egecioglu, Emil. Engel, Jörgen A.. Jerlhag, Elisabet. Addiction Biology.
Source: wiley.com

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS: The issue related to macrovascular

Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS: The issue related to macrovascular outcomes and intensive glycemic control was hotly debated after the publication of landmark trials like ACCORD, ADVANCE, and VADT. The only benefits seem to come from intervening...
Source: hindawi.com